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Abstract
Cushing’s disease (CD) is caused by a pituitary adenoma secreting corticotrophin (ACTH) that leads to cortisol excess. Despite a characteristic 
clinical picture, it is often difficult to make a proper diagnosis, as it requires complex and long-lasting diagnostic procedures. Selective trans-
sphenoidal surgery (TSS) remains the treatment of choice for CD. Untreated or improperly treated Cushing’s disease leads to the development 
of serious complications, which lower patients’ quality of life. Mortality in this group is high, reaching 50% within a 5-year follow-up period. 
In this study, we present our own experience and discuss the importance of preoperative hormone measurements, magnetic resonance 
imaging (MRI) of the pituitary, results of histopathological examination (immunohistochemical and ultrastructural in electron microscopy) and post-
operative early and late hormonal assessment in the aspect of TSS efficacy. The performed analysis is based on the current criteria for 
remission of Cushing’s disease. Our study emphasises the need for long-term postoperative endocrinological follow-up, which facilitates 
early detection of recurrent hypercortisolemia. (Endokrynol Pol 2012; 63 (5): 398–403)
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Streszczenie
Przyczyną choroby Cushinga jest gruczolak przysadki wydzielający kortykotropinę (ACTH) i prowadzący do nadczynności kory nadnerczy. 
Mimo charakterystycznego obrazu klinicznego trudne jest prawidłowe rozpoznanie, wymaga złożonej i długotrwałej diagnostyki endo-
krynologicznej. Leczeniem z wyboru pozostaje selektywna, przezklinowa operacja guza przysadki. Nieleczona lub źle leczona choroba 
Cushinga prowadzi do rozwoju poważnych powikłań, które przyczyniają się do obniżenia jakości życia pacjentów. Śmiertelność w tej 
grupie dotyczy 50% chorych w czasie 5-letniej obserwacji. 
Autorzy opracowania prezentują doświadczenia własne i omawiają znaczenie przedoperacyjnych oznaczeń hormonalnych, obrazowania 
przysadki mózgowej metodą rezonansu magnetycznego, wyników badania histopatologicznego (oceny immunohistochemicznej i ultrastrukturalnej 
w mikroskopie elektronowym) oraz pooperacyjnej wczesnej i odległej oceny hormonalnej w aspekcie skuteczności leczenia neurochirurgicz-
nego. Dokonana analiza opiera się na obowiązujących kryteriach remisji choroby Cushinga. W opracowaniu podkreślono konieczność 
długoletniego, pooperacyjnego nadzoru endokrynologicznego, który umożliwia wczesne wykrycie nawrotu hiperkortyzolemii. (Endokrynol 
Pol 2012; 63 (5): 398–403)
Słowa kluczowe: choroba Cushinga, desmopresyna, gruczolak przysadki, kortyzol, operacja przezklinowa, rezonans magnetyczny, test hamowania 
deksametazonem
Introduction
Cushing’s disease (CD) is the commonest cause of endog-
enous hypercortisolemia. The disease incidence is estimated 
at 1–3 cases per 1 million people per year with its peak ob-
served in the 3rd–5th decades of life. The disease affects 
women 4–8 times more often than men. In the under-10 
year-old age group, Cushing’s disease is diagnosed 
sporadically and is the least common cause of hyper-
cortisolemia. After puberty, an increase in the incidence 
rate is observed [1–4]. During pregnancy, Cushing’s dis-
ease constitutes about 30% of all causes of endogenous 
hypercortisolemia [2–5]. Diagnosis of the disease and its 
treatment remain one of the major challenges in modern 
endocrinology [2, 3, 6]. In about 95% of cases, CD is caused 
by ACTH — secreting pituitary adenoma. In other, rare, cases 
it results from diffuse corticotroph hyperplasia. Most com-
monly, a corticotroph tumour is less than 1 cm in diameter 
(microadenoma). Only in about 15% of cases does at least 
one tumour diameter exceed 1 cm (macroadenoma) [2–4]. 
In patients with Cushing’s disease, pituitary corticotroph 
adenoma exhibits autonomous ACTH secretion. This means 
that adenoma cells are not under inhibitory control of nega-
tive feedback mechanism. ACTH synthesis and secretion in 
the pituitary and cortisol secretion from the adrenals become 
independent from the needs of the organism. This affects the 
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circadian rhythm, which results in high ACTH and cortisol 
concentrations being maintained even during late evening 
hours and at night. Hypercortisolemia inhibits secretory 
function of normal pituitary corticotrophic cells, exerting 
no effect on neoplastic cells [2–4]. There also occur changes 
within the receptor profile of pituitary corticotroph cells, 
especially in terms of increased expression of corticotrophin-
releasing hormone (CRH) receptors as well as V3 vasopressin 
receptors [7–11]. 
Excessive cortisol secretion leads to the development of 
somatic symptoms of Cushing’s syndrome. These include: 
facial plethora, purple striae, muscular atrophy, and the 
redistribution of adipose tissue with its accumulation in 
the face, nape and abdomen. Gradually, hypercortisolemia 
complications develop, such as arterial hypertension, glucose 
homeostasis alterations, decreased bone mineral density, 
venous thromboembolic disease, and increased frequency of 
infections. There are also observed cognitive function im-
pairment, circadian rhythm disturbances and sleeping 
disorders. CD sometimes causes psychotic symptoms 
resulting from vasogenic and metabolic damage to the 
brain structures and cerebral atrophy associated with 
the disease. These complications result in both a decreased 
quality of life and shortened survival time. As many as half 
of untreated patients will die within five years [2, 4, 12–14].
Surgical treatment for cushing’s disease
Transsphenoidal selective adenomectomy is the treat-
ment of choice in Cushing’s disease [2, 15]. The small size 
of most ACTH-secreting adenomas, the proximity of critical 
structures such as the optic chiasm and internal carotid arter-
ies, and the possibility of inflicting irreversible damage to the 
pituitary require transsphenoidal surgery to be performed 
only by experienced neurosurgeons in reference centres [2]. 
Surgical procedures performed by experienced neuro-
surgeons have high efficacy. This, depending on the site, 
ranges from 60% to over 90%. However, the recurrence 
rate that follows even an initially effective surgical treat-
ment is high, and reaches 20–25% within five years [15]. 
Each successive surgical treatment is technically more 
difficult and yields a poorer outcome than the first one, 
with a higher probability of developing postoperative 
complications such as anterior pituitary insufficiency 
and/or diabetes insipidus. Therefore all patients who 
have undergone surgical treatment for corticotrophic 
pituitary adenomas require prolonged endocrinological 
follow-up [2, 3, 15]. 
Preoperative hormone measurements
Hormone measurements are of vital importance for 
the diagnosis of Cushing’s disease. In each case it is 
necessary to measure plasma ACTH, serum cortisol 
and urinary free cortisol (UFC) under basic conditions. 
Assessment of morning serum cortisol following a 1 mg 
dexamethasone suppression test is of significant diag-
nostic importance [2, 4]. The commonly performed tests 
also include the so-called “high-dose” dexamethasone 
suppression test (HDDST; 2 mg q.i.d. during two consec-
utive days) with assessment of UFC or 17-hydroxyster-
oids excretion in daily urine. The CRH stimulation test 
(100 μg i.v.) is the most commonly performed dynamic 
test [4]. Desmopressin stimulation test (DDAVP; 10 μg 
i.v.) is not a part of routine diagnostic procedures [4, 16], 
yet according to recommendations it may be performed 
within scientific studies and the obtained results could 
constitute a basis for a re-assessment of its usefulness 
after gathering more data [16].
Inasmuch as preoperative tests are of key importance 
for the diagnosis of ACTH-dependent Cushing’s syn-
drome as well as for its clinical picture and number of 
complications, they do not directly influence the efficacy 
of TSS. This is applicable both to basic measurements of 
plasma ACTH, serum and urinary cortisol and excretion 
of cortisol metabolites in daily urine, as well as results 
of the hormone measurements following HDDST. It is 
confirmed both by data from literature and our own 
observations [17, 18]. 
Magnetic resonance imaging
In addition to hormone measurements, MRI of the 
pituitary is also of significant importance in pre-
operative diagnostics. The procedure is performed 
according to a special protocol based on adequately 
‘dense’ cross-sections, as the majority of corticotroph 
adenomas are microadenomas, with half of them be-
ing less than 5 mm in diameter. The MRI scans should 
be performed before and after intravenous injection 
of the contrast agent (gadolinium; Gd-DTPA) [4]. The 
typical MRI of a corticotroph adenoma is presented 
in Figure 1.
There have been disagreements in the literature 
as to the importance of preoperative visualisation 
of corticotroph adenomas and its impact on the 
effectiveness of surgical treatment. A multicentre 
retrospective analysis performed by Bochicchio, 
Losa et al. demonstrated that accurate preoperative 
localisation of a focal lesion in MR imaging of the 
pituitary gland is associated with greater effective-
ness of surgical treatment, whereas the lack of such 
a localisation is associated with a poorer prognosis [19]. 
However, the study, which was based on observa-
tions from 25 European endocrinological centres, did 
not separately assess the effectiveness of treatment 
in a sub-group of corticotroph pituitary micro- and 
macroadenomas [19]. 
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Figure 1. Magnetic resonance imaging of the different types of ACTH-secreting pituitary adenomas — authors` own material. A. 
Coincidence of an empty sella and a minute ACTH-secreting pituitary adenoma located close to the left cavernous sinus; B. Pituitary 
microadenoma; C. Intra- and suprasellar pituitary macroadenoma; D. pituitary macroadenoma with right cavernous sinus invasion 
and destruction of the sella turcica floor
Rycina 1. Obrazy MRI gruczolaków kortykotropowych przysadki u chorych z chorobą Cushinga — materiał własny autorów. 
A. Współistnienie pustego siodła i gruczolaka kortykotropowego przysadki zlokalizowanego po lewej stronie siodła tureckiego; B. 
Mikrogruczolak przysadki; C. Śród- i nadsiodłowy makrogruczolak przysadki; D. Makrogruczolak przysadki mózgowej naciekający 
prawą zatokę jamistą i niszczący dno siodła tureckiego
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A study conducted by British authors, based on 
retrospective assessment of 16 cases of patients with 
pituitary macroadenomas, demonstrated that treat-
ment effectiveness in this group of patients is low [20]. 
Only two of 16 patients were surgically cured (12.5%) 
and in five patients (31.3%) it was possible to achieve 
remission after supplementary radiotherapy. In as yet 
unpublished material of ours, we found the effective-
ness of surgical treatment of patients with pituitary 
macroadenoma to be greater than or equal to as much 
as 50%. 
 A separate issue, seemingly affecting about 10–15% 
of patients with biochemically confirmed Cushing’s 
disease, is lack of an accurately localised focal lesion 
within the pituitary gland. In this difficult clinical situa-
tion, one can consider the performance of the so-called 
diagnostic sellar exploration, which in some cases leads 
to removal of a lesion of the type characteristic of CT 
and a visually undetectable by MR pituitary microad-
enoma (e.g. less than 3 mm in diameter) and remission 
of Cushing’s disease [21]. 
Immunohistochemical and ultrastructural 
assessment
Histological assessment supplemented by immu-
nohistochemical staining is an essential element of 
Cushing’s disease diagnostics. A positive test result 
is the ultimate and explicit confirmation that the 
pathological lesion within the pituitary caused the 
development of ACTH-dependent hypercortisolemia. 
This is why a neurosurgeon while performing 
a surgical procedure should meticulously collect the 
tissue specimens removed in the course of the TSS 
and send it to a pathology laboratory experienced 
in examining and assessing pituitary tumours. In the 
light of previous retrospective studies [19, 22] and 
our own observations [23] it should be stated that 
a positive result of an immunohistochemical and/or 
ultrastructural examination is more commonly as-
sociated with remission of Cushing’s disease. The 
histology, immunochemistry and ultrastructure of 
typical corticotroph adenoma is presented in Figure 2.
Furthermore, it seems that positive pathological 
examination results are of particular significance in 
patients with equivocal results of MR imaging of the pi-
tuitary. In such cases, confirmation of neoplastic tissue in 
immunohistochemical and ultrastructural examination 
may make total removal of a small corticotroph pituitary 
tumour more worthwhile. In patients with corticotroph 
macroadenomas (particularly those with features of 
infiltration of adjacent structures) one should expect 
absence of cure, despite positive result of a pathological 
examination. This results from the fact that removal of 
only a small part of a large corticotroph tumour obvi-
ously translates to a positive result of histopathological, 
immunohistochemical and ultrastructural examina-
tions, with simultaneous lack of surgical completeness 
and persistence of Cushing’s disease [23].
Postoperative hormonal assessment
In recent years, increasing importance has been at-
tached to the so-called early postoperative hormone 
assessment. This consists of measuring serum cortisol 
concentration during the first week after transsphe-
noidal surgery (optimally on the first, second or third 
day). Clinical observations demonstrate that achieve-
ment of the so-called subnormal cortisol levels (i.e. 
< 2.0 μg/dL) is an indicator of surgical treatment ef-
ficacy forecasting persistent remission of CD [2, 17, 24, 
25]. In a prospective, as yet unpublished, study assess-
ing the effectiveness of surgical treatment of ACTH-
secreting pituitary adenomas, we confirmed disease 
remission in all patients with cortisol concentrations 
lower than 2.5 μg/dL on the first day after surgical 
treatment. Furthermore, lack of remission or disease 
recurrence was observed in all patients with cortisol 
concentrations more than or equal to 2.5 μg/dL. 
A major advantage of early postoperative assess-
ment of serum cortisol is the possibility of immediate 
detection and selecting those patients in whom the 
TSS was ineffective. In some of those patients, it is 
possible to perform repeated transsphenoidal surgery 
(sellar re-exploration) during the same hospital stay 
[24, 26]. Assessment based on early measurements of 
serum cortisol is limited by the possibility of obtain-
ing low (or even subnormal) cortisol levels during 
the first days after the TSS in patients prepared with 
high doses of adrenal steroidogenesis inhibitors (i.e. 
ketokonazol) [2]. 
A separate and interesting issue is the use of ACTH 
and cortisol desmopressin stimulation test in assessment 
of surgical treatment effectiveness [9–11, 27]. Its use is 
based on the confirmed presence of V3 vasopressin 
receptors expressed in pituitary corticotroph tumours 
[7–11]. In the persistent presence of neoplastic tissue, 
which is characterised by autonomous ACTH secretion, 
after desmopressin stimulation there occurs a significant 
(≥ 30%) increase in ACTH and cortisol (≥ 20%) secre-
tion in more than 85% of corticotroph adenoma cases. 
Its advantage (as opposed to the CRH test) lies in its 
easy availability and lower costs. However, the main 
objection raised against this test is the possibility of V3 
receptors being present on normal corticotroph cells of 
the pituitary, although the frequency of this phenom-
enon has not been explicitly determined. However, in 
order to eliminate the possibility of normal corticotroph 
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Figure 2. Histopathology, immunochemistry and ultrastructure of corticotroph pituitary adenomas. A. Histopathology of corticotroph 
pituitary adenoma. Note the uniformity of the cells and loss of the typical, acinar architecture of the pituitary (light microscopy; H&E; 
original magnification × 20); B. Strong immunostaining for ACTH in corticotroph pituitary adenoma (light microscopy, original 
magnification × 20); C. Ultrastructural features of densely granulated corticotroph pituitary adenoma with typical abundant endoplasmic 
reticulum and Golgi complex. Notice numerous intra-plasmatic secretory granules (original magnification × 4,800); D. Ultrastructural 
features of sparsely granulated corticotroph pituitary adenoma with typical well-differentiated intracellular organelles (endoplasmic 
reticulum, Golgi complex, minor mitochondria and small, intra-plasmatic secretory granules; original magnification × 4,800)
Rycina 2. Obrazy histopatologiczne, immunohistochemia i ultrastruktura gruczolaków kortykotropowych przysadki. A. Histopatologia 
gruczolaka kortykotropowego w mikroskopii świetlnej (H&E; powiększenie oryginalne × 20). Zwraca uwagę jednorodność komórek 
i utrata typowego, zrazikowego utkania przysadki; B. Barwienie immunohistochemiczne skrawków guza kortykotropowego wykazujące 
silny, dodatni odczyn dla ACTH w mikroskopii świetlnej (powiększenie oryginalne × 20); C. Bogatoziarnisty gruczolak kortykotropowy 
przysadki w badaniu ultrastrukturalnym z rozbudowanym retikulum endoplazmatycznym i układem Golgiego. Widoczne liczne 
śródplazmatyczne ziarnistości wydzielnicze (mikroskop elektronowy, powiększenie oryginalne × 4800); D. Ubogoziarnisty gruczolak 
kortykotropowy przysadki w badaniu ultrastrukturalnym. Widoczne typowe, dobrze zróżnicowane struktury śródplazmatyczne (retikulum 
endoplazmatycze, układ Golgiego drobne mitochondria, małe, nieliczne, okrągłe ziarnistości wydzielnicze; (mikroskop elektronowy, 
powiększenie oryginalne × 4800)
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cells stimulation by desmopressin, some authors have 
suggested applying a modification of this test consist-
ing in the administration of 1 mg dexamethasone eight 
hours before the administration of 10 μg desmopressin 
bolus. This combined dexamethasone suppression and 
desmopressin stimulation test facilitates the inhibition of 
normal pituitary corticotroph cells and the stimulation 
of neoplastic cells only [10, 27]. 
Our own experience and data available in literature 
concerning the use of desmopressin test (including 
the one preceded by 1 mg oral dexamethasone) dem-
onstrate its usefulness for a selected group of patients 
[9–11, 27]. Given the typical course of Cushing’s disease 
recurrence with evident clinical symptoms, a pituitary 
adenoma visible in MRI and typical results of hormone 
measurements is not difficult to diagnose. Cases of 
atypical, moderately intensified ACTH-dependent 
hypercortisolemia, particularly those with unclear re-
sults of imaging examinations (postoperatively altered 
morphology in the sellar region, lack of adenoma fea-
tures in MRI) are frequently associated with diagnostic 
difficulties and limitations. 
An obtained positive result of a desmopressin 
stimulation test makes easier a diagnosis of persistent 
ACTH-dependent hypercortisolemia and also makes 
deciding on sellar re-exploration easier. However, the 
test described must not be interpreted irrespective 
of other clinical data and — until more experience 
is acquired — should be regarded as an auxiliary 
diagnostic tool [16]. 
Summary
Cushing’s disease remains a challenge both for endocri-
nologists and neurosurgeons. The high percentage of 
recurrence, even after initially effective transsphenoidal 
surgery, requires meticulous and long-term monitoring 
in the postoperative period. A favourable prognosis is 
associated with the achievement of subnormal serum 
cortisol in the early postoperative period, confirmation 
of corticotroph adenoma presence in a histopathologi-
cal examination of removed specimens, and persistent 
postoperative adrenal insufficiency, requiring long-term 
hydrocortisone replacement therapy. An unfavourable 
prognosis seems to be associated with: the presence of 
pituitary macroadenoma, lack of precise localisation of 
the tumour in MRI of the pituitary, and previous inef-
fective surgical treatment. 
Persistent ACTH and cortisol response in the desmo-
pressin stimulation test seems to be a useful, auxiliary, 
diagnostic tool in a selected group of patients. Preopera-
tive results of hormone concentration measurements 
are of no importance in terms of predicting surgical 
treatment efficacy.
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